The role of dyslipidemia and obesity in the pathogenesis of osteonecrosis of the femoral head

The review focuses on current concepts of the role of obesity, the chronic systemic inflammation it induces, and lipid metabolism disorders in the pathogenesis of osteonecrosis of the femoral head (ONFH) in order to substantiate new approaches to its prevention and treatment. This review analyzes modern fundamental and clinical studies focusing on the relationship between metabolic disorders, chronic inflammation, and osteonecrosis. Specifically, we examine research investigating the molecular mechanisms of adipose tissue dysfunction, lipotoxicity, oxidative stress, and their impact on bone tissue homeostasis.
The analysis established that obesity acts as a systemic risk factor for ONFH development, functioning not merely as a source of mechanical load but also as an initiator of a pathogenic cascade. Dysfunctional adipose tissue leads to chronic low-grade systemic inflammation and oxidative stress. Together, these factors provoke endothelial dysfunction, impair perfusion of the femoral head bone tissue, and induce lipotoxicity in the bone marrow. Consequently, at the local level, this cascade suppresses osteogenesis, simultaneously enhances bone resorption, and triggers osteocyte apoptosis.
Systemic metabolic and inflammatory disruptions initiated by obesity underlie impaired bone remodeling, ischemia, and necrosis of the femoral head subchondral bone. Therefore, the correction of body weight and associated metabolic disorders should be considered an integral part of a comprehensive strategy for treating ONFH and preventing its progression. This integrated approach may improve the outcomes of joint-preserving interventions and delay the need for total hip arthroplasty in young patients.

1. Quan H., Ren C., He Y., Wang F., Dong S., Jiang H. Application of biomaterials in treating early osteonecrosis of the femoral head: research progress and future perspectives. Acta Biomater. 2023;164:15–73. DOI: 10.1016/j.actbio.2023.04.005.

2. Quan H., Ren C., Xie H., He Z., Ding H., Li J. et al. An injectable hydrogel loaded with miRNA nanocarriers promotes vessel-associated osteoclast (VAO)-mediated angiogenesis and bone regeneration in osteonecrosis of the rat femoral head. Biomaterials. 2025;320:123252. DOI: 10.1016/j.biomaterials.2025.123252.

3. Konarski W., Poboży T., Śliwczyński A., Kotela I., Krakowiak J., Hordowicz M. et al. Avascular necrosis of femoral head-overview and current state of the art. Int. J. Environ. Res. Public Health. 2022;19(12):7348. DOI: 10.3390/ijerph19127348.

4. Zheng C., Wu Y., Xu J., Liu Y., Ma J. Exosomes from bone marrow mesenchymal stem cells ameliorate glucocorticoid-induced osteonecrosis of femoral head by transferring microRNA-210 into bone microvascular endothelial cells. J. Orthop. Surg. Res. 2023;18(1):939. DOI: 10.1186/s13018-023-04440-x.

5. Konarski W., Poboży T., Konarska K., Śliwczyński A., Kotela I., Hordowicz et al. Osteonecrosis related to steroid and alcohol use-an update on pathogenesis. Healthcare (Basel). 2023;11(13):1846. DOI: 10.3390/healthcare11131846.

6. Müller T.D., Blüher M., Tschöp M.H., DiMarchi R.D. Anti-obesity drug discovery: advances and challenges. Nat. Rev. Drug Discov. 2022;21(3):201–223. DOI: 10.1038/s41573-021-00337-8.

7. Khanna D., Khanna S., Khanna P., Kahar P., Patel B.M. Obesity: a chronic low-grade inflammation and its markers. Cureus. 2022;14(2):e22711. DOI: 10.7759/cureus.22711.

8. Lin X., Li H. Obesity: epidemiology, pathophysiology, and therapeutics. Front. Endocrinol. (Lausanne). 2021;12:706978. DOI: 10.3389/fendo.2021.706978.

9. Peng W., Zhang L., Wen F., Tang X., Zeng L., Chen J. et al. Trends and disparities in non-communicable diseases in the Western Pacific region. Lancet Reg. Health West Pac. 2023;43:100938. DOI: 10.1016/j.lanwpc.2023.100938.

10. Müller T.D., Blüher M., Tschöp M.H., DiMarchi R.D. Anti-obesity drug discovery: advances and challenges. Nat. Rev. Drug. Discov. 2022;21(3):201–223. DOI: 10.1038/s41573-021-00337-8.

11. Yan Y., Wang J., Wang Y., Wu W., Chen W. Research on lipidomic profiling and biomarker identification for osteonecrosis of the femoral head. Biomedicines. 2024;12(12):2827. DOI: 10.3390/biomedicines12122827.

12. Yu X., Zhang S., Zhang B., Dai M. Relationship of idiopathic femoral head necrosis with blood lipid metabolism and coagulation function: A propensity score-based analysis. Front. Surg. 2023;9:938565. DOI: 10.3389/fsurg.2022.938565.

13. Baek S.H., Kim K.H., Lee W.K., Hong W., Won H., Kim S.Y. Abnormal lipid profiles in nontraumatic osteonecrosis of the femoral head: a comparison with osteoarthritis using propensity score matching. J. Bone Joint Surg. Am. 2022;104(Suppl. 2):19–24. DOI: 10.2106/JBJS.20.00520.

14. Wang C., Cen C., Su H., Peng Y., Wang T., Li J. et al. Integrated multi-omics analysis identifies lipid metabolism biomarkers in ONFH and reveals therapeutic potential of retinoic acid. Sci. Rep. 2025;15(1):30716. DOI: 10.1038/s41598-025-13703-y.

15. George G., Lane J.M. Osteonecrosis of the femoral head. J. Am. Acad. Orthop. Surg. Glob. Res. Rev. 2022;6(5):e21.00176. DOI: 10.5435/JAAOSGlobal-D-21-00176.

16. Yu X., Dou S., Lu L., Wang M., Li Z., Wang D. Relationship between lipid metabolism, coagulation and other blood indices and etiology and staging of non-traumatic femoral head necrosis: a multivariate logistic regression-based analysis. J. Orthop. Surg. Res. 2024;19(1):251. DOI: 10.1186/s13018-024-04715-x.

17. Toribio-Fernández R., Tristão-Pereira C., Carlos SillaCastro J., Callejas S., Oliva B., Fernandez-Nueda I. et al. Apolipoprotein E-ε2 and Resistance to Atherosclerosis in Midlife: The PESA Observational Study. Circ. Res. 2024;134(4):411–424. DOI: 10.1161/CIRCRESAHA.123.323921.

18. Chen Y., Zhou Z., Che H., Li D. Lipid metabolism and osteonecrosis: unraveling causal mechanisms via multi-omics and mendelian randomization. Front. Physiol. 2025;16:1642153. DOI: 10.3389/fphys.2025.1642153.

19. Ren Y., Deng Z., Gokani V., Kutschke M., Mitchell T.W., Aruwajoye O. et al. Anti-interleukin-6 therapy decreases hip synovitis and bone resorption and increases bone formation following ischemic osteonecrosis of the femoral head. J. Bone Miner. Res. 2021;36(2):357–368. DOI: 10.1002/jbmr.4191.

20. Li L., Zhao S., Leng Z., Chen S., Shi Y., Shi L. et al. Pathological mechanisms and related markers of steroid-induced osteonecrosis of the femoral head. Ann. Med. 2024;56(1):2416070. DOI: 10.1080/07853890.2024.2416070.

21. Posor Y., Jang W., Haucke V. Phosphoinositides as membrane organizers. Nat. Rev. Mol. Cell Biol. 2022;23(12):797–816. DOI: 10.1038/s41580-022-00490-x.

22. Motta F., Timilsina S., Gershwin M.E., Selmi C. Steroid-induced osteonecrosis. J. Transl. Autoimmun. 2022;5:100168. DOI: 10.1016/j.jtauto.2022.100168.

23. Yan Y., Wang J., Huang D., Lv J., Li H., An J. et al. Plasma lipidomics analysis reveals altered lipids signature in patients with osteonecrosis of the femoral head. Metabolomics. 2022;18(2):14. DOI: 10.1007/s11306-022-01872-0.

24. Taylor E.B. The complex role of adipokines in obesity, inflammation, and autoimmunity. Clin. Sci. (Lond.). 2021;135(6):731–752. DOI: 10.1042/CS20200895.

25. Singh S., Anshita D., Ravichandiran V. MCP-1: Function, regulation, and involvement in disease. Int. Immunopharmacol. 2021;101(Pt. B):107598. DOI: 10.1016/j.intimp.2021.107598.

26. Planat-Benard V., Varin A., Casteilla L. MSCs and inflammatory cells crosstalk in regenerative medicine: concerted actions for optimized resolution driven by energy metabolism. Front. Immunol. 2021;12:626755. DOI: 10.3389/fimmu.2021.626755.

27. Romacho T., Valencia I., Ramos-González M., Vallejo S., López-Esteban M., Lorenzo O. et al. Visfatin/eNampt induces endothelial dysfunction in vivo: a role for toll-like receptor 4 and NLRP3 inflammasome. Sci. Rep. 2020;10(1):5386. DOI: 10.1038/s41598-020-62190-w.

28. Obradovic M., Sudar-Milovanovic E., Soskic S., Essack M., Arya S., Stewart A.J. et al. Leptin and obesity: role and clinical implication. Front. Endocrinol. (Lausanne). 2021;12:585887. DOI: 10.3389/fendo.2021.585887.

29. Ghanbari M., Momen Maragheh S., Aghazadeh A., Mehrjuyan S.R., Hussen B.M., Abdoli Shadbad M. et al. Interleukin-1 in obesity-related low-grade inflammation: from molecular mechanisms to therapeutic strategies. Int. Immunopharmacol. 2021;96:107765. DOI: 10.1016/j.intimp.2021.107765.

30. Calabrese L., Fiocco Z., Satoh T.K., Peris K., French L.E. Therapeutic potential of targeting interleukin-1 family cytokines in chronic inflammatory skin diseases. Br. J. Dermatol. 2022;186(6):925–941. DOI: 10.1111/bjd.20975.

31. Lee S.H., Park S.Y., Choi C.S. Insulin resistance: from mechanisms to therapeutic strategies. Diabetes Metab. J. 2022;46(1):15–37. DOI: 10.4093/dmj.2021.0280.

32. Zhang H., Zhang X., Wang S., Zheng L., Guo H., Ren Y. et al. Adipocyte-derived exosomal miR-22-3p modulated by circadian rhythm disruption regulates insulin sensitivity in skeletal muscle cells. J. Biol. Chem. 2023;299(12):105476. DOI: 10.1016/j.jbc.2023.105476.

33. Ma M., Jiang W., Zhou R. DAMPs and DAMP-sensing receptors in inflammation and diseases. Immunity. 2024;57(4):752–771. DOI: 10.1016/j.immuni.2024.03.002.

34. Fahed G., Aoun L., Bou Zerdan M., Allam S., Bou Zerdan M., Bouferraa Y. et al. Metabolic syndrome: updates on pаthophysiology and management in 2021. Int. J. Mol. Sci. 2022;23(2):786. DOI: 10.3390/ijms23020786.

35. Xiang M., Yin M., Xie S., Shi L., Nie W., Shi B. et al. The molecular mechanism of neutrophil extracellular traps and its role in bone and joint disease. Heliyon. 2023;9(12):e22920. DOI: 10.1016/j.heliyon.2023.e22920.

36. Nonokawa M., Shimizu T., Yoshinari M., Hashimoto Y., Nakamura Y., Takahashi D. et al. Association of neutrophil extracellular traps with the development of idiopathic osteonecrosis of the femoral head. Am. J. Pathol. 2020;190(11):2282–2289. DOI: 10.1016/j.ajpath.2020.07.008.

37. Li C., Guo H., Han Z., Wang T., Wu D., Yang Z. et al. Association of the systemic immune inflammation index with failure after core decompression for osteonecrosis of the femoral head: a prospective time-to-event analysis. Ann. Med. 2025;57(1):2566867. DOI: 10.1080/07853890.2025.2566867.

38. Sánchez-de-Diego C., Pedrazza L., Pimenta-Lopes C., Martinez-Martinez A., Dahdah N., Valer J.A. et al. NRF2 function in osteocytes is required for bone homeostasis and drives osteocytic gene expression. Redox. Biol. 2021;40:101845. DOI: 10.1016/j.redox.2020.101845.

39. Szumilas K., Szumilas P., Słuczanowska-Głąbowska S., Zgutka K., Pawlik A. Role of adiponectin in the pathogenesis of rheumatoid arthritis. Int. J. Mol. Sci. 2020;21(21):8265. DOI: 10.3390/ijms21218265.

40. Zorena K., Jachimowicz-Duda O., Ślęzak D., Robakowska M., Mrugacz M. Adipokines and obesity. Potential link to metabolic disorders and chronic complications. Int. J. Mol. Sci. 2020;21(10):3570. DOI: 10.3390/ijms21103570.

41. Al-Mansoori L., Al-Jaber H., Prince M.S., Elrayess M.A. Role of inflammatory cytokines, growth factors and adipokines in adipogenesis and insulin resistance. Inflammation. 2022;45(1):31–44. DOI: 10.1007/s10753-021-01559-z.

42. Li C., Cheng H., Adhikari B.K., Wang S., Yang N., Liu W. et al. The role of apelin-APJ system in diabetes and obesity. Front. Endocrinol. (Lausanne). 2022;13:820002. DOI: 10.3389/fendo.2022.820002.

43. Fibbi B., Marroncini G., Naldi L., Peri A. The yin and yang effect of the apelinergic system in oxidative stress. Int. J. Mol. Sci. 2023;24(5):4745. DOI: 10.3390/ijms24054745.

44. Lebiedzinska-Arciszewska M., Pakula B., Bonora M., Missiroli S., Potes Y., Jakubek-Olszewska P. et al. Distribution of the p66Shc adaptor protein among mitochondrial and mitochondria-associated membranes fractions in normal and oxidative stress conditions. Int. J. Mol. Sci. 2024;25(23):12835. DOI: 10.3390/ijms252312835.

45. Li J., Deng C., Liang W., Kang F., Bai Y., Ma B. et al. Mn-containing bioceramics inhibit osteoclastogenesis and promote osteoporotic bone regeneration via scavenging ROS. Bioact. Mater. 2021;6(11):3839–3850. DOI: 10.1016/j.bioactmat.2021.03.039.

46. Shimasaki M., Ueda S., Ichiseki T., Hirata H., Kawahara N., Ueda Y. Resistance of bone marrow mesenchymal stem cells in a stressed environment – comparison with osteocyte cells. Int. J. Med. Sci. 2021;18(6):1375–1381. DOI: 10.7150/ijms.52104.

47. Marchi S., Guilbaud E., Tait S.W.G., Yamazaki T., Galluzzi L. Mitochondrial control of inflammation. Nat. Rev. Immunol. 2023;23(3):159–173. DOI: 10.1038/s41577-022-00760-x.

48. Harapas C.R., Idiiatullina E., Al-Azab M., Hrovat-Schaale K., Reygaerts T., Steiner A. et al. Organellar homeostasis and innate immune sensing. Nat. Rev. Immunol. 2022;22(9):535–549. DOI: 10.1038/s41577-022-00682-8.

49. Decout A., Katz J.D., Venkatraman S., Ablasser A. The cGAS-STING pathway as a therapeutic target in inflammatory diseases. Nat. Rev. Immunol. 2021;21(9):548–569. DOI: 10.1038/s41577-021-00524-z.

50. Iliushchenko D., Efimenko B., Mikhailova A.G., Shamanskiy V., Saparbaev M.K., Matkarimov B.T. et al. Deciphering the foundations of mitochondrial mutational spectra: replication-driven and damage-induced signatures across chordate classes. Mol. Biol. Evol. 2025;42(2):msae261. DOI: 10.1093/molbev/msae261.